- Current report filing (8-K)
December 01 2009 - 10:28AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): November 30, 2009
SHENGTAI
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
Delaware
(State
or other jurisdiction of incorporation)
|
000-51312
(Commission
File
Number)
|
54-2155579
(IRS
Employer
Identification
No.)
|
|
|
Changda Road East
Development
District, Changle County
Shandong, PRC 262400
(Address
of principal executive offices)
|
262400
(Zip
Code)
|
Registrant’s
telephone number, including area code:
011-86-536-218-2777
Copies to:
Benjamin
Tan, Esq.
Sichenzia
Ross Friedman Ference LLP
61
Broadway, 32 Floor
New York,
New York 10006
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communication
s pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 5.02
Departure of
Directors or Principal Officers; Election of Directors; Appointment of Principal
Directors
On
November 30, 2009, our Chief Financial Officer, Ms. Yiru Shi resigned from her
position as, Chief Financial Officer with immediate effect. Ms.
Shi cited the desire to pursue other career goals as the reason for her
resignation. On the same day, the Company’s board of directors
accepted her resignation.
Also on
November 30, 2009, the Company’s board of directors appointed Mr. Yongqiang Wang
to assume the position of the Company’s new Chief Financial Officer with
immediate effect.
Mr.
Wang’s annual salary is $96,000 payable monthly and in accordance with customary
payroll practices.
Mr. Wang,
40, graduated with an Associates degree from the Shandong Economic and
Management Institute. He joined Weifang Shengtai in April 2006 as the assistant
to the General Manager of the Accounts Department and was in charged of the
finance department. He assumed the position of Deputy General Manager of the
Accounts Department in February 2007. Prior to joining us, Mr. Wang worked as a
financial manager for various enterprises. Mr. Wang is also a
director of the Company and has held the position since May 15,
2007.
There are
no family relationships between Mr. Wang and our directors or executive
officers.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICALS, INC.
|
|
|
|
|
Dated:
November 30, 2009
|
|
|
By:
/s/ Qingtai
Liu
|
|
Name:
Qingtai Liu
|
|
Title:
Chief Executive
Officer
|
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From May 2024 to Jun 2024
Shengtai Pharmaceutical (GM) (USOTC:SGTI)
Historical Stock Chart
From Jun 2023 to Jun 2024